par Zhong, Jixin;Zhang, Shu;Kuczma, Michal;Kraj, Piatr;Xu, Jun Fa;Gong, Feili;Zhou, Jianfeng;Wen, Li;Eizirik, Decio L. ;Du, Jie;Wang, Wei;Yu, Qilin;Wang, Cong-Yi;Yang, Ping;Rao, Xiaoquan;Longueville, Hervé ;Fang, Jing;Tu, Yaqin;Zhang, Zhijun;Lai, Qiaohong
Référence Journal of autoimmunity, 53, C, page (95-104)
Publication Publié, 2014
Référence Journal of autoimmunity, 53, C, page (95-104)
Publication Publié, 2014
Article révisé par les pairs
Résumé : | Unlike genetic alterations, epigenetic modifications are reversible and amenable to pharmacological interventions, which make them appealing targets for clinical therapy. However, little is known about epigenetic regulation in experimental autoimmune encephalomyelitis (EAE). Here we demonstrated that methyl-CpG-binding domain protein 2 (MBD2), an epigenetic regulator, controls autoimmunity and EAE through T-bet/Hlx. Tbx21 and Hlx underwent a DNA methylation turnover upon polarizations and a unique methylation pattern was essential for T |